Bad news: if you were still hoping to get one of the $400 juicers from Juicero, you may be out of luck. Juicero announced that they were suspending sales while they seek an acquirer. They'd already dropped the juicer's price from its initial $700 earlier this year and had hoped to find ways to drop it further, but ran out of time. I keep thinking: if they'd been a health care company, they not only might still be in business but also would probably be looking to raise their prices. Juicero once was the darling of investors. It raised $120 million from a variety of respected funding sources, including Kleiner Perkins, Alphabet and Campbell Soup. They weren't a juice company, or even an appliance company. They were a technology company! They had an Internet-of-Things product! They had an ongoing base of customers...
cancer treatment
See the following -
Can Doctors Teach The Body To Cure Cancer?
Increasingly, doctors are using their patients' own immune systems as valuable weapons against the disease...
- Login to post comments
CEO Roundtable On Cancer Launches The Project Data Sphere Initiative, A New Data Sharing And Analytic Platform For Cancer Patient Benefit
Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (www.ProjectDataSphere.org), with the goal of advancing research to improve the lives of cancer patients and their families around the world...
- Login to post comments
CSIR In Advanced Phase Of Gene Sequencing Under Its Genome Variation Consortium Project
Council of Scientific and Industrial Research (CSIR) is in an advanced phase of study of Indian Genome Variation Consortium Project. The researchers are now working towards predictive and personalized medicine with an objective to provide quicker treatment options to treat infectious diseases and life style disorders...
- Login to post comments
First-Ever Crowdsourced Prostate Cancer Data-Mining Competition Discovery Impacts and Predicts Patient Survival
Today, a breakthrough report in the international journal Lancet Oncology demonstrates how a collaborative effort to analyze broadly accessible clinical data led to novel insights and improvements in cancer treatment and management. Participants in the Prostate Cancer DREAM (Dialogue for Reverse Engineering Assessments and Methods) Challenge – an effort initiated by Project Data Sphere, LLC (PDS) in collaboration with Sage Bionetworks using proven DREAM methodology – developed new risk factor models for metastatic castration-resistant prostate cancer (mCRPC)...
- Login to post comments
Halamka Says We Can and Must Improve Healthcare Management
As a physician and CIO, I’m quick to spot inefficiencies in healthcare workflow. More importantly, as the care navigator for my family, I have extensive firsthand experience with patient facing processes. My wife’s cancer treatment, my father’s end of life care, and my own recent primary hypertension diagnosis taught me how we can do better. Last week, when my wife received a rejection in coverage letter from Harvard Pilgrim/Caremark, it highlighted the imperative we have to improve care management workflow in the US. Since completing her estrogen positive, progesterone positive, HER2 negative breast cancer treatment in 2012 (chemotherapy, surgery, radiation), she’s been maintained on depot lupron and tamoxifen to suppress estrogen...
- Login to post comments
Health Care's Juicero Problem
- Login to post comments
Improved Survival In Cancer Patients With High Vitamin D Levels
Researchers have again found that higher levels of circulating vitamin D on diagnosis of cancer are associated with significantly better survival and remission rates. The new findings come from a comprehensive meta-analysis involving more than 17,000 cancer patients, published online in the April 29 issue of the Journal of Clinical Endocrinology and Metabolism...
- Login to post comments
NCI Plans Database Of Patients Who Experience Miraculous Recoveries
Every clinical trial has its outliers. Some patients respond far better to the treatment than the rest, but the focus on efficacy across the study population means these results--and their implications--are lost in the shuffle.
- Login to post comments